Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.

Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, Takahashi Y, Tsuji M, Kasahara Y, Takata Y, Okada M.

PLoS One. 2014 Feb 26;9(2):e89516. doi: 10.1371/journal.pone.0089516. eCollection 2014.

2.

Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.

Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, Nishino M, Stern D, Okada M.

Psychogeriatrics. 2013 Sep;13(3):164-9. doi: 10.1111/psyg.12021. Epub 2013 Jun 11.

3.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
4.

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG.

Int J Geriatr Psychiatry. 2005 Oct;20(10):938-44.

PMID:
16163744
5.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
6.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

7.

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.

Tai SY, Chen CH, Chien CY, Yang YH.

BMC Neurol. 2017 Feb 23;17(1):40. doi: 10.1186/s12883-017-0800-y.

8.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
9.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
10.

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S.

J Am Geriatr Soc. 1999 May;47(5):570-8.

PMID:
10323651
11.

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.

Dement Geriatr Cogn Disord. 2005;19(4):189-95. Epub 2005 Jan 25.

PMID:
15677866
12.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

13.
15.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
16.

The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil.

Müller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H.

J Neural Transm Suppl. 2006;(71):27-30.

PMID:
17447412
17.

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T.

J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9.

18.

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS.

Lancet Neurol. 2008 Apr;7(4):310-8. doi: 10.1016/S1474-4422(08)70046-2. Epub 2008 Feb 28.

PMID:
18296124
19.

Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.

Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y, Kotler M, Weizman A, Rabey JM.

Clin Neuropharmacol. 2003 Jan-Feb;26(1):12-7.

PMID:
12567159
20.

A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study.

Arai H, Takahashi T.

Am J Geriatr Psychiatry. 2009 Apr;17(4):353-4. doi: 10.1097/JGP.0b013e31819431ea. No abstract available.

PMID:
19307864

Supplemental Content

Support Center